Cantor Fitzgerald Reiterates Overweight Rating for Ascendis Pharma A/S (NASDAQ:ASND)

Cantor Fitzgerald restated their overweight rating on shares of Ascendis Pharma A/S (NASDAQ:ASND) in a research report sent to investors on Tuesday morning,Benzinga reports. The firm currently has a $170.00 price objective on the biotechnology company’s stock.

Several other research analysts have also recently issued reports on ASND. Wedbush reissued an “outperform” rating and set a $181.00 price target on shares of Ascendis Pharma A/S in a report on Friday, November 15th. JPMorgan Chase & Co. increased their target price on shares of Ascendis Pharma A/S from $165.00 to $167.00 and gave the company an “overweight” rating in a report on Wednesday, January 29th. Oppenheimer dropped their target price on shares of Ascendis Pharma A/S from $190.00 to $180.00 and set an “outperform” rating for the company in a report on Friday, November 15th. Stifel Nicolaus increased their target price on shares of Ascendis Pharma A/S from $200.00 to $207.00 and gave the company a “buy” rating in a report on Friday, November 15th. Finally, UBS Group started coverage on shares of Ascendis Pharma A/S in a report on Tuesday, January 7th. They issued a “buy” rating and a $196.00 target price for the company. Two investment analysts have rated the stock with a hold rating and thirteen have given a buy rating to the company. According to data from MarketBeat.com, Ascendis Pharma A/S currently has an average rating of “Moderate Buy” and an average target price of $193.43.

Ascendis Pharma A/S Stock Up 13.0 %

NASDAQ ASND opened at $142.49 on Tuesday. The stock has a market capitalization of $8.65 billion, a P/E ratio of -17.63 and a beta of 0.64. Ascendis Pharma A/S has a 52-week low of $111.09 and a 52-week high of $161.00. The firm has a 50-day moving average price of $132.19 and a 200 day moving average price of $132.29.

Ascendis Pharma A/S (NASDAQ:ASND) last posted its quarterly earnings results on Wednesday, February 12th. The biotechnology company reported ($0.68) earnings per share (EPS) for the quarter, topping the consensus estimate of ($1.32) by $0.64. On average, equities research analysts expect that Ascendis Pharma A/S will post -7.12 earnings per share for the current fiscal year.

Institutional Trading of Ascendis Pharma A/S

A number of hedge funds have recently bought and sold shares of ASND. Signaturefd LLC boosted its position in Ascendis Pharma A/S by 13.2% during the third quarter. Signaturefd LLC now owns 686 shares of the biotechnology company’s stock worth $102,000 after acquiring an additional 80 shares during the last quarter. China Universal Asset Management Co. Ltd. boosted its position in Ascendis Pharma A/S by 63.8% during the third quarter. China Universal Asset Management Co. Ltd. now owns 11,142 shares of the biotechnology company’s stock worth $1,664,000 after acquiring an additional 4,338 shares during the last quarter. Rice Hall James & Associates LLC boosted its position in Ascendis Pharma A/S by 5.9% during the third quarter. Rice Hall James & Associates LLC now owns 160,614 shares of the biotechnology company’s stock worth $23,981,000 after acquiring an additional 8,958 shares during the last quarter. Pursue Wealth Partners LLC acquired a new stake in Ascendis Pharma A/S during the third quarter worth approximately $217,000. Finally, Harbor Capital Advisors Inc. boosted its position in Ascendis Pharma A/S by 67.2% during the third quarter. Harbor Capital Advisors Inc. now owns 87,302 shares of the biotechnology company’s stock worth $13,035,000 after acquiring an additional 35,102 shares during the last quarter.

Ascendis Pharma A/S Company Profile

Ascendis Pharma A/S, a biopharmaceutical company, focuses on developing therapies for unmet medical needs. It offers SKYTROFA for treating patients with growth hormone deficiency (GHD). The company is also developing a pipeline of three independent endocrinology rare disease product candidates in clinical development, as well as focuses on advancing oncology therapeutic candidates.